Construct validity and reproducibility of the Prescription Opioid Misuse And Abuse Questionnaire (POMAQ)

References

• Dahlhamer J, Lucas J, Zelaya C, et al. Prevalence of chronic pain and high-impact chronic pain among adults – United States, 2016. Morb Mortal Wkly Rep. 2018;67(36):1001–1006.
   PubMed Web of Science ®Google Scholar
• Duenas M, Ojeda B, Salazar A, et al. A review of chronic pain impact on patients, their social environment and the health care system. J Pain Res. 2016;9:457–467.
   PubMed Web of Science ®Google Scholar
• Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain – United States, 2016. MMWR Recomm Rep. 2016;65(1):1–49.
   PubMed Web of Science ®Google Scholar
• Turk DC, Wilson HD, Cahana A. Treatment of chronic non-cancer pain. Lancet. 2011;377(9784):2226–2235.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. 2018 Annual surveillance report of drug-related risks and outcomes—United States: Surveillance Special Report. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services; August 31, 2018. [cited 2019 February 21]. Available from: https://www.cdc.gov/drugoverdose/pdf/pubs/2018-cdc-drug-surveillance-report.pdf
   Google Scholar
• Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2017 National Survey on Drug Use and Health (HHS Publication No. SMA 18-5068, NSDUH Series H-53). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2018. [cited 2019 March 13]. Available from: https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/NSDUHFFR2017/NSDUHFFR2017.pdf
   Google Scholar
• Department of Health and Human Services (HHS). HHS acting secretary declares public health emergency to address national opioid crisis 2017. [cited 2018 October 24]. Available from: https://www.hhs.gov/about/news/2017/10/26/hhs-acting-secretary-declares-public-health-emergency-address-national-opioid-crisis.html
   Google Scholar
• Institute of Medicine (IOM). Relieving pain in America: a blueprint for transforming prevention, care, education, and research. Washington, DC: National Academies Press; 2011.
   Google Scholar
• Coplan PM, Cepeda MS, Petronis KR, et al. Postmarketing studies program to assess the risks and benefits of long-term use of extended-release/long-acting opioids among chronic pain patients. Postgrad Med. 2020;132(1):44–51.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (FDA). Labeling Supplement and PMR Required 2013. [cited 2018 October 24]. Available from: https://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM367697.pdf
   Google Scholar
• Belgrade MJ, Schamber CD, Lindgren BR. The DIRE score: predicting outcomes of opioid prescribing for chronic pain. J Pain. 2006;7(9):671–681.
   PubMed Web of Science ®Google Scholar
• Butler SF, Budman SH, Fernandez KC, et al. Development and validation of the current opioid misuse measure. Pain. 2007;130(1–2):144–156.
   PubMed Web of Science ®Google Scholar
• Butler SF, Fernandez K, Benoit C, et al. Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). J Pain. 2008;9(4):360–372.
   PubMed Web of Science ®Google Scholar
• Coambs R, Jarry J, Santhiapillai A, et al. The SISAP: a new screening instrument for identifying potential opioid abusers in the management of chronic nonmalignant pain within general medical practice. Pain Res Manage. 1996;1(3):155–162.
   Google Scholar
• Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med. 2005;6(6):432–442.
   PubMed Web of Science ®Google Scholar
• Setnik B, Roland CL, Barsdorf AI, et al. The content validation of the Self-Reported Misuse, Abuse and Diversion of Prescription Opioids (SR-MAD) instrument for use in patients with acute or chronic pain. Curr Med Res Opin. 2017;33(6):1067–1076.
   PubMed Web of Science ®Google Scholar
• Coyne KS, Barsdorf AI, Brooks A, editors. Content Validity of the Prescription Opioid Misuse and Abuse Questionnaire (POMAQ) among chronic pain patients. ISPOR 22nd Annual International Meeting; 2017. May 20–24; Boston, MA, USA.
   Google Scholar
• Coyne KS, Barsdorf AI, Brooks A, et al. Establishing the content validity of the Prescription Opioid Misuse and Abuse Questionnaire (POMAQ) among chronic pain patients. Curr Med Res Opin. 2020. DOI:10.1080/03007995.2020.1865891
   Google Scholar
• Food and Drug Administration (FDA). Guidance for industry on patient-reported outcome measures: use in medical product development to support labeling claims. Fed Regist. 2009;74(235):65132–65133.
   Google Scholar
• Souza AC, Alexandre NMC, Guirardello EB. Psychometric properties in instruments evaluation of reliability and validity. Epidemiol Serv Saude. 2017;26(3):649–659.
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med. 1993;118(8):622–629.
   PubMed Web of Science ®Google Scholar
• Smith SM, Dart RC, Katz NP, et al. Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. Pain. 2013;154(11):2287–2296.
   PubMed Web of Science ®Google Scholar
• Dorrance KA, Ramchandani S, Neil N, et al. Leveraging the military health system as a laboratory for health care reform. Mil Med. 2013;178(2):142–145.
   PubMed Web of Science ®Google Scholar
• Compton P, Darakjian J, Miotto K. Screening for addiction in patients with chronic pain and “problematic” substance use: evaluation of a pilot assessment tool. J Pain Symptom Manage. 1998;16(6):355–363.
   PubMed Web of Science ®Google Scholar
• Compton PA, Wu SM, Schieffer B, et al. Introduction of a self-report version of the Prescription Drug Use Questionnaire and relationship to medication agreement noncompliance. J Pain Symptom Manage. 2008;36(4):383–395.
   PubMed Web of Science ®Google Scholar
• First MB, Spitzer RL, Gibbon M, et al. Structured clinical interview for DSM-IV® Axis I Disorders (SCID-I), clinician version, administration booklet. Washington (DC): AMerican Psychiatric Pub Inc; 1997.
   Google Scholar
• Lobbestael J, Leurgans M, Arntz A. Inter-rater reliability of the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID I) and Axis II Disorders (SCID II). Clin Psychol Psychother. 2011;18(1):75–79.
   PubMed Web of Science ®Google Scholar
• Skre I, Onstad S, Torgersen S, et al. High interrater reliability for the Structured Clinical Interview for DSM-III-R Axis I (SCID-I). Acta Psychiatr Scand. 1991;84(2):167–173.
   PubMed Web of Science ®Google Scholar
• Williams JB, Gibbon M, First MB, et al. The structured clinical interview for DSM-III-R (SCID). II. Multisite test-retest reliability. Arch Gen Psychiatry. 1992;49(8):630–636.
   PubMed Web of Science ®Google Scholar
• Zanarini MC, Frankenburg FR, Hennen J, et al. The longitudinal course of borderline psychopathology: 6-year prospective follow-up of the phenomenology of borderline personality disorder. Am J Psychiatry. 2003;160(2):274–283.
   PubMed Web of Science ®Google Scholar
• Zanarini MC, Skodol AE, Bender D, et al. The collaborative longitudinal personality disorders study: reliability of axis I and II diagnoses. J Pers Disord. 2000;14(4):291–299.
   PubMed Web of Science ®Google Scholar
• Michna E, Ross EL, Hynes WL, et al. Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. J Pain Symptom Manage. 2004;28(3):250–258.
   PubMed Web of Science ®Google Scholar
• Wasan AD, Butler SF, Budman SH, et al. Does report of craving opioid medication predict aberrant drug behavior among chronic pain patients? Clin J Pain. 2009;25(3):193–198.
   PubMed Web of Science ®Google Scholar
• Manimala YS, Gautam S, Reddy BG. Mass spectrometry: an analytical method. J Pharm Anal. 2016;5(2):118–125.
   Google Scholar
• Center for Substance Abuse Treatment. Appendix B. Urine collection and testing procedures and alternative methods for monitoring drug use. Treatment improvement protocol: substance abuse: clinical issues in intensive outpatient treatment. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2006.
   Google Scholar
• Byrt T, Bishop J, Carlin JB. Bias, prevalence and kappa. J Clin Epidemiol. 1993;46(5):423–429.
   PubMed Web of Science ®Google Scholar
• Coyne KS, Barsdorf AI, Currie BM, et al. Insight into chronic pain in the United States: descriptive results from the Prescription Opioid Misuse and Abuse Questionnaire (POMAQ) validation study. Curr Med Res Opin. 2020. DOI:10.1080/03007995.2020.1865889.
   Google Scholar
• Gryczynski J, Schwartz RP, Mitchell SG, et al. Hair drug testing results and self-reported drug use among primary care patients with moderate-risk illicit drug use. Drug Alcohol Depend. 2014;141:44–50.
   PubMed Web of Science ®Google Scholar